Cargando…

The Present and Future of Yellow Fever Vaccines

The disease yellow fever (YF) is prevented by a live-attenuated vaccine, termed 17D, which has been in use since the 1930s. One dose of the vaccine is thought to give lifelong (35+ years) protective immunity, and neutralizing antibodies are the correlate of protection. Despite being a vaccine-preven...

Descripción completa

Detalles Bibliográficos
Autores principales: Hansen, Clairissa A., Barrett, Alan D. T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468696/
https://www.ncbi.nlm.nih.gov/pubmed/34577591
http://dx.doi.org/10.3390/ph14090891
_version_ 1784573737226469376
author Hansen, Clairissa A.
Barrett, Alan D. T.
author_facet Hansen, Clairissa A.
Barrett, Alan D. T.
author_sort Hansen, Clairissa A.
collection PubMed
description The disease yellow fever (YF) is prevented by a live-attenuated vaccine, termed 17D, which has been in use since the 1930s. One dose of the vaccine is thought to give lifelong (35+ years) protective immunity, and neutralizing antibodies are the correlate of protection. Despite being a vaccine-preventable disease, YF remains a major public health burden, causing an estimated 109,000 severe infections and 51,000 deaths annually. There are issues of supply and demand for the vaccine, and outbreaks in 2016 and 2018 resulted in fractional dosing of the vaccine to meet demand. The World Health Organization (WHO) has established the “Eliminate Yellow Fever Epidemics” (EYE) initiative to reduce the burden of YF over the next 10 years. As with most vaccines, the WHO has recommendations to assure the quality, safety, and efficacy of the YF vaccine. These require the use of live 17D vaccine only produced in embryonated chicken eggs, and safety evaluated in non-human primates only. Thus, any second-generation vaccines would require modification of WHO recommendations if they were to be used in endemic countries. There are multiple second-generation YF vaccine candidates in various stages of development that must be shown to be non-inferior to the current 17D vaccine in terms of safety and immunogenicity to progress through clinical trials to potential licensing. The historic 17D vaccine continues to shape the global vaccine landscape in its use in the generation of multiple licensed recombinant chimeric live vaccines and vaccine candidates, in which its structural protein genes are replaced with those of other viruses, such as dengue and Japanese encephalitis. There is no doubt that the YF 17D live-attenuated vaccine will continue to play a role in the development of new vaccines for YF, as well as potentially for many other pathogens.
format Online
Article
Text
id pubmed-8468696
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84686962021-09-27 The Present and Future of Yellow Fever Vaccines Hansen, Clairissa A. Barrett, Alan D. T. Pharmaceuticals (Basel) Review The disease yellow fever (YF) is prevented by a live-attenuated vaccine, termed 17D, which has been in use since the 1930s. One dose of the vaccine is thought to give lifelong (35+ years) protective immunity, and neutralizing antibodies are the correlate of protection. Despite being a vaccine-preventable disease, YF remains a major public health burden, causing an estimated 109,000 severe infections and 51,000 deaths annually. There are issues of supply and demand for the vaccine, and outbreaks in 2016 and 2018 resulted in fractional dosing of the vaccine to meet demand. The World Health Organization (WHO) has established the “Eliminate Yellow Fever Epidemics” (EYE) initiative to reduce the burden of YF over the next 10 years. As with most vaccines, the WHO has recommendations to assure the quality, safety, and efficacy of the YF vaccine. These require the use of live 17D vaccine only produced in embryonated chicken eggs, and safety evaluated in non-human primates only. Thus, any second-generation vaccines would require modification of WHO recommendations if they were to be used in endemic countries. There are multiple second-generation YF vaccine candidates in various stages of development that must be shown to be non-inferior to the current 17D vaccine in terms of safety and immunogenicity to progress through clinical trials to potential licensing. The historic 17D vaccine continues to shape the global vaccine landscape in its use in the generation of multiple licensed recombinant chimeric live vaccines and vaccine candidates, in which its structural protein genes are replaced with those of other viruses, such as dengue and Japanese encephalitis. There is no doubt that the YF 17D live-attenuated vaccine will continue to play a role in the development of new vaccines for YF, as well as potentially for many other pathogens. MDPI 2021-09-01 /pmc/articles/PMC8468696/ /pubmed/34577591 http://dx.doi.org/10.3390/ph14090891 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hansen, Clairissa A.
Barrett, Alan D. T.
The Present and Future of Yellow Fever Vaccines
title The Present and Future of Yellow Fever Vaccines
title_full The Present and Future of Yellow Fever Vaccines
title_fullStr The Present and Future of Yellow Fever Vaccines
title_full_unstemmed The Present and Future of Yellow Fever Vaccines
title_short The Present and Future of Yellow Fever Vaccines
title_sort present and future of yellow fever vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468696/
https://www.ncbi.nlm.nih.gov/pubmed/34577591
http://dx.doi.org/10.3390/ph14090891
work_keys_str_mv AT hansenclairissaa thepresentandfutureofyellowfevervaccines
AT barrettalandt thepresentandfutureofyellowfevervaccines
AT hansenclairissaa presentandfutureofyellowfevervaccines
AT barrettalandt presentandfutureofyellowfevervaccines